Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors by Perez-Pineiro, Rolando et al.
Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione
Reductase Inhibitors
Rolando Perez-Pineiro,*
,† Asdrubal Burgos,
† Deuan C. Jones,
‡ Lena C. Andrew,
3 Hortensia Rodriguez,
§ Margarita Suarez,
§
Alan H. Fairlamb,
‡ and David S. Wishart*
,†
Department of Biological Sciences and Computing Science, UniVersity of Alberta, Edmonton, Alberta, Canada T6G 2E8, DiVision of Biological
Chemistry & Drug DiscoVery, College of Life Sciences, UniVersity of Dundee, Dundee DD1 5EH, United Kingdom, Laboratorio de Sı ´ntesis
Orga ´nica, Facultad de Quı ´mica, UniVersidad de la Habana, 10400 Ciudad Habana, Cuba
ReceiVed October 16, 2008
The implementation of a novel sequential computational approach that can be used effectively for
virtual screening and identiﬁcation of prospective ligands that bind to trypanothione reductase (TryR)
is reported. The multistep strategy combines a ligand-based virtual screening for building an enriched
library of small molecules with a docking protocol (AutoDock, X-Score) for screening against the
TryR target. Compounds were ranked by an exhaustive conformational consensus scoring approach
that employs a rank-by-rank strategy by combining both scoring functions. Analysis of the predicted
ligand-protein interactions highlights the role of bulky quaternary amine moieties for binding afﬁnity.
The scaffold hopping (SHOP) process derived from this computational approach allowed the identiﬁcation
of several chemotypes, not previously reported as antiprotozoal agents, which includes dibenzothiepine,
dibenzooxathiepine, dibenzodithiepine, and polycyclic cationic structures like thiaazatetracyclo-nonadeca-
hexaen-3-ium. Assays measuring the inhibiting effect of these compounds on T. cruzi and T. brucei
TryR conﬁrm their potential for further rational optimization.
Introduction
Trypanosomatids are parasitic protozoa responsible for
several tropical diseases of which African sleeping sickness
(Trypanosoma brucei gambiense and T. b. rhodesiense),
Chagas disease (T. cruzi), and the different forms of
leishmaniasis (Leishmania donoVani and L. infantum) are
considered the most lethal.
1 At present, the chemotherapies
associated with all forms of trypanosomiasis have many
deﬁciencies including poor efﬁcacy, toxicity to humans, high
cost, and the emergence of drug-resistant parasitic strains.
2
Unfortunately, because of the low proﬁt margins associated
with developing improved therapies for tropical diseases,
there is little motivation for the pharmaceutical industry to
develop better tropical disease drugs. Accordingly, many
agencies, including the Special Program for Research and
Training in Tropical Diseases at the World Health Organiza-
tion (WHO/TDR), numerous academic research groups,
various international/national bodies, and philanthropic foun-
dations, have been supporting the discovery of new drug
candidates for a number of tropical diseases.
3
One of the most promising strategies to develop potent
and speciﬁc antiparasitic drugs relies on the exploitation of
metabolic differences between the pathogen and the host. The
mammalian redox defense system, based on the glutathione/
glutathione reductase (GR
a) couple, is replaced in trypano-
somatids by an analogous, but distinct, system based on the
thiol-polyamine conjugate trypanothione and the ﬂavoen-
zyme trypanothione reductase
4 (Figure 1). The almost total
mutual substrate exclusivity of these two enzymes and the
essential role of TryR in the survival of all trypanosomatids
studied so far have served as the basis for rational design of
many types of selective inhibitors of TryR in the presence
of host GR.
5,6
Structure-based drug design
7 (SBDD) has emerged as a very
effective and low-cost strategy to improve the rate of success
at any stage of the drug discovery pipeline. There are two broad
categories of SBDD computational techniques: (1) protein-ligand
docking and (2) ligand similarity methods. Protein-ligand
docking attempts to use the 3D protein structure of the protein
target to predict binding modes and afﬁnities of ligands to
biologically relevant targets, while ligand-similarity methods
capitalize on the fact that ligands similar to an active ligand
are more likely to be active than random ligands. The latter
method considers two- or three-dimensional chemistry, shape,
electrostatic, and interaction points (e.g., pharmacophore points)
to assess similarity.
The discovery and optimization of antiparasitic compounds
has also proﬁted from the use of computational docking
techniques.
8 The elucidation of the 3D structure of TryR in free
form
9-11 and complexed with NADPH,
11 glutathionylspermi-
dine,
12 trypanothione,
13 the competitive inhibitor quinacrine
14
and its alkylating derivative quinacrine mustard,
15 have all
provided detailed information about the interactions involved
in enzyme recognition and substrate binding. Despite this, TryR
has been the target of just a few computational approaches and
only modest results have been obtained so far. For instance
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rithm
16 to predict binding afﬁnity of ligands to TryR. The
validity of this docking model is particularly noteworthy in
relation to similar computational approaches because it predicted
an interaction between the alkyl amino moiety of the acridine
ring and the side chain of Glu 19 as observed in the crystal
structure of the TryR-quinacrine complex.
14 The discovery of
the macrocyclic alkaloid lunarine
13 and the recent identiﬁcation
of chlorhexidine and its derivatives
17 via high-throughput virtual
screening are successful examples of the employment of
structure-based methodologies to identify novel TryR inhibitors.
At present. trypanothione reductase still poses a tremendous
challenge for medicinal chemists. The active site of TryR is
extremely wide and it allows for multiple binding orientations
and/or the simultaneous accommodation of more than one
inhibitor.
15,18,19 In addition, protein-ligand interactions of even
very similar compounds can be unpredictable.
20,21 For these
reasons, the search for novel structure-based strategies with the
ability to identify more potent and selective TryR inhibitors is
desirable. In this context, we have decided that the combination
of ligand similarity and protein docking strategies in a single
workﬂow could be useful for this purpose. The fact that both
methods, when used individually, focus only on one part of the
structural information available has recently prompted the
development of hybrid similarity-based docking methods. These
hybrid methods aim at fully exploiting all the structural
information present in ligand-bound protein structures, both from
the protein and ligand perspective.
22-24 In principle, a strategy
combining 3D ligand similarity and protein docking should
provide more accurate prediction about ligand binding modes.
25
Although the majority of ligand similarity-based methods for
molecular comparisons, compound classiﬁcations, or database
searching utilize molecular descriptors for the deﬁnition of
chemical reference spaces,
26 it has been demonstrated that
molecular fragment proﬁles could also be successfully employed
as queries for database searching and that signiﬁcant recovery
rates could be achieved.
27 Fragment proﬁles differ from mo-
lecular ﬁngerprints
28 because, on the one hand, they do not
organize predeﬁned or catalogued descriptors in a speciﬁc
manner, and on the other, they are based on the randomization
of structural information rather than canonical bit string
representations.
Stemming from our interest in the development of new
antiprotozoal drugs,
29 we report herein the ﬁrst implementation
of a novel virtual screening cascade protocol that can be used
effectively for virtual screening and identiﬁcation of prospective
ligands that bind to trypanothione reductase. To validate this
strategy, we used TryR inhibition assays to measure the activity
of 19 of these prospective ligands and we found that many of
them exhibit sufﬁciently promising characteristics to warrant
further ligand optimization. The novelty of this approach lies
in the sequential combination of a similarity virtual screening
based on fragment proﬁle comparisons facilitated through the
calculation of compound class-speciﬁc fragment frequencies
using naive Bayesian statistics, with a docking protocol (Au-
toDock and X-Score) for screening against the TryR target.
Another important feature of this computational approach is the
enhancement of its predictive power by incorporating an
exhaustive conformational consensus scoring process using a
rank-by-rank strategy in order to provide a list of suitable
compounds to be considered for bioscreening.
Computational Methods
The computational approach we developed for screening
molecules binding to TryR combines both ligand similarity and
protein docking methods within an integrated framework. A
ﬂowchart describing various phases of the virtual screening
cascade protocol is shown in Figure 2.
Similarity-Based Virtual Screening. The Molinspiration
virtual screening “miscreen”
30 was selected as the base meth-
odology to perform the ligand-based virtual screening. Brieﬂy,
the “miscreen” toolkit ﬁrst analyses a training set of active
structures to build a usable ligand model and then compares it
with inactive molecules by using sophisticated Bayesian sta-
tistics. On the basis of this analysis, a bioactivity model is
developed, where for each substructure fragment a bioactivity
contribution is calculated. Once a model is built, the bioactivity
of the screened molecules may be then calculated as a sum of
the activity contributions of the fragments in these molecules.
This approach provides an “activity score” for each compound,
which represents the probability that the particular molecule will
have the desired biological activity. The higher this score, the
higher the probability that the compound will be active.
The construction of the initial training set was based on inhibition
mode criteria. Molecules that bind reversibly to trypanothione
reductase constitute the largest group of inhibitors studied so far
and are among the most effective with inhibition constant (Ki)
values, usually in the low micromolar range.
5,6 To date, the only
reports about the structural determination of TryR complexed with
a non-natural substrate are related to the competitive inhibitor
quinacrine
14 and its chloro derivative, quinacrine mustard.
15 The
availability of these structures certainly provides some useful
insights into how these type of ligands ﬁt into the active site of
the enzyme and the interactions involved.
In principle, a single active molecule is sufﬁcient to build a
usable model, but larger fragment populations have higher
Figure 1. Structure of trypanothione (T(S)2) and the reaction catalyzed by trypanothione that reduces T(S)2 to dihydrotrypanothione, T(SH)2.
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resolution and increasingly accurate compound ranking. The
initial training set was assembled using 135 molecules extracted
from different bibliographic sources (see Supporting Informa-
tion) and selected according to their inhibition mode and high
binding afﬁnity proﬁles. Only compounds with Ki values ranging
between 0.1-50 µM were considered. As expected, the majority
of the chosen compounds fell into one of the three known
general categories of reversible TryR inhibitors: hydrophobic
polyamines, tricyclic compounds, and diphenylsulfane deriva-
tives (Figure 3).
Compounds included in the training set were transformed to
SMILES coordinates to generate a bioactivity model. The
distribution of antiprotozoal activity for 100000 molecules with
druglike properties extracted from PubChem by diversity
selection to represent the average druglike chemical space and
the training set of active structures is shown in Figure 4.
According to this diagram, the bioactivity model provides a good
separation between active compounds and the average back-
ground. Subsequently, in silico screening of the ZINC database
(http://zinc.docking.org/), containing over eight million purchas-
able compounds, was performed by calculating the bioactivity
of each molecule as a sum of activity contributions of fragments.
A data set of 1312 compounds, listed according to their activity
score, typically between 4.3 (higher score) and 1 (lower score),
was retrieved.
The “miscreen” virtual screening is very fast (ca. 100000
molecules may be screened in less than an hour) permitting the
processing of very large molecular libraries.
ADME/Tox Filtering. Filtering of the output data set derived
from the similarity-based virtual screening (1312 compounds)
was performed by FAF-Drugs
31 (http://bioserv.rpbs.jussieu.fr/
Help/FAF Drugs.html). This online service, based on Frowns
(a chemoinformatics toolkit), allows users to process their own
compound collections via simple ADME/Tox ﬁltering rules such
as molecular weight, polar surface area, LogP, or number of
rotatable bonds. Notably, FAF-Drugs turned out to be very
convenient in our case because its customizable protocol allowed
us to input ﬁltering criteria not only related with bioavailability
issues but also with substrate speciﬁcity. In contrast to GR, the
active site of TryR shows an overall negative charge and is
much wider and more hydrophobic.
32 Therefore, special atten-
tion was given to the input values of total charge (0-2+), LogP
(1-5), and molecular mass (200-500). The rest of the
parameters were either in compliance with Lipinski’s rule of
ﬁve or set as default. Compounds matching the ﬁltering criteria
(603 molecules) comprised the enriched library to be used as
input data for docking studies.
Clustering Analysis of the Enriched Library. One of the
advantages of using a virtual screening protocol based on
Bayesian statistics is that it can generalize, i.e., it is able to
learn general structure requirements that are necessary for
bioactivity. As a result, the newly identiﬁed bioactive molecules
not only contain building blocks found in the training set.
Furthermore, the protocol is also able to identify new chemo-
types via a process called scaffold hopping (SHOP). To shed
some light about this point, clustering analysis of the initial
training set and the enriched library was carried out through
LibMCS,
33 a stand-alone application program, part of the
JKlustor package. LibraryMCS clusters a set of chemical
structures in a hierarchical manner based on the concept of
maximum common substructure (MCS). The LibMCS program
Figure 2. Workﬂow diagram of the virtual screening cascade protocol.
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Structures that share a large common substructure (a core or
scaffold structure) are grouped together. In the next step, these
cores are clustered to form the next level in the hierarchy. Two
hierarchical clusterings, corresponding to the initial training set
and the enriched library, respectively, are depicted in Figure 5.
Initial structures are found at the bottom of the hierarchy, and
the next level contains the MCS of clusters of initial molecules.
The highest clustering values observed for the enriched library
(cluster level: 4, total cluster count: 257), Figure 5B, with respect
Figure 3. General representation of structural templates included in the initial training set.
Figure 4. Distribution of antiprotozoal activity for average background molecules and the training set based on the bioactivity model.
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101), Figure 5A, conﬁrms the effectiveness of the adopted
similarity-based strategy to generate new chemotypes by using
the information of already known bioactive molecules.
Docking Studies. Virtual docking was performed using the
Lamarckian genetic algorithm implemented in AutoDock4.
34
This is commonly regarded as best of the three docking methods
in AutoDock in terms of its ability to ﬁnd the lowest energy
and its structure prediction accuracy.
35 The protein structure
for the unbound Trypanosoma cruzi trypanothione reductase was
chosen as the target, and coordinates were downloaded from
the Protein Data Bank (PDB code 1AOG).
36 Prior to docking,
FAD cofactors and water molecules were removed manually
from the PDB ﬁle. Polar hydrogens were added using the
AutoDock Tools interface. Grid maps were prepared using the
AutoGrid utility with 126 × 126 × 102 points and grid spacing
set to 0.204 Å. Docking parameters modiﬁed from the defaults
were: number of individuals in the population (set to 300),
maximum number of energy evaluations (set to 2500000),
maximum number of generations (set to 2700), and number of
hybrid GA-LS runs (set to 100).
Initial conformations of the ligands were placed next to the
aromatic ring of Tyr111, a central residue in the active site
having a hydrophobic interaction with trypanothione. All
rotatable bonds in the ligands were allowed to rotate during
the docking trials. Because amino acid positions in the enzyme
were found, experimentally, to change insigniﬁcantly upon
binding the native substrate,
12,13 the active site was assumed to
be rigid and therefore nonﬂexible docking was carried out.
Ligand structures (603) were taken from version 8.0 of the ZINC
Database.
37 For some compounds that were not available in the
ZINC Database, sets of coordinates were generated by submit-
ting their SMILE strings to ZINC’s user upload utility. In-house
Perl scripts were used to extract the 100 conformations generated
by AutoDock from the docking output ﬁle for each of the
compounds in order to allow them to be evaluated by the
program X-Score.
38 All ligand ﬁles that had the same LogP
values calculated by X-Score were inspected visually to verify
their structures. Compounds whose ﬁles were found to be
incorrect had their SMILE strings submitted to ZINC’s user
upload utility to regenerate their three-dimensional structures
and were rescreened. To minimize the computing time, docking
jobs as well as X-Score evaluations were carried out on a
WestGrid computer cluster designed for serial processing and
parallel jobs (http://www.westgrid.ca). Jobs were submitted
using portable batch system (PBS) ﬁles invoking either Au-
toDock or X-Score.
In-house Perl scripts were used to extract the top conforma-
tions for each compound docked to the protein. Pymol v0.99
39
was used to visualize the compounds docked to the active site
of the protein, and schematic diagrams of protein-ligand
interactions were obtained by the Ligplot program.
40
Consensus Scoring. Combining multiple scoring functions
has been shown in various virtual database screening studies to
be an effective way for improving hit rates.
41 While AutoDock
is one of the most cited docking programs
42 and has recorded
many successes in virtual screening approaches,
43 the stand-
alone scoring function X-Score has shown good correlations
between theoretical and experimentally determined protein-ligand
binding afﬁnities.
44 Consequently, X-Score was combined in
this study with the function implemented in the AutoDock
program to provide a list of ligands sorted by consensus scoring
adopting the rank-by-rank strategy.
45 AutoDock and X-Score
were applied to rank all the conformations generated by the
603 compounds (60300 conformations in total). For each
conformation, the ﬁnal rank was calculated as the average rank
from the two scoring functions. Only the best scored conforma-
tion of each compound was considered for ranking the 603
ligands.
Results and Discussion
Docking Analysis and Enzymatic Assays. A representation
of the 20 top ranked ligands according to consensus scoring is
shown in Figure 6. These compounds exhibit structural char-
acteristics typical of several known TryR inhibitors, including
extended hydrophobic moieties tethered to positive charge
fragments mostly represented by bulky quaternary cyclic amines.
The latter feature agrees with the previous ﬁnding that positive
charges play a crucial role for ligand binding in the active site
of TryR.
19,46 Phenothiazines and diphenylsulfanes, included in
the initial training set, were successfully recovered among the
top scored ligands, highlighting the importance of these building
blocks for binding afﬁnity. The presence of a chloro substituent
is another common structural motif found in the retrieved
molecules. In the TryR-Quinacrine complex, the chlorine atom
is close to the ring nitrogen of Trp22. Obviously the halogen is
stabilized by interacting with the positively polarized hydrogen
of the indolyl nitrogen. The same type of interaction is also
very likely to occur for some of the newly identiﬁed chloro
derivatives.
To test the efﬁcacy of our computational protocol, 19
compounds were screened for inhibition using a high-throughput
microplate assay previously developed for this purpose.
47 The
Figure 5. Hierarchical clustering dendogram (A) training set, (B)
enriched library. Blue rectangle denotes molecules that share the same
common structure highlighted in red.
1674 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 6 Perez-Pineiro et al.tested set included 10 of the best rank structures according
consensus scoring (compounds 1-7, 10, 12, 16, Figure 6).
Additionally, some of the best hits by Autodock (21) and
X-Score (22, 23, 24) and several high-ranked new chemotypes
(25-29) depicted in Figure 7, were also considered for
screening. Compounds were tested in triplicate against both T.
cruzi and T. brucei. The mean Z′ value
48 over the total 19 testing
plates was 0.88 (range 0.56-0.96), indicating a well performing
Figure 6. Top 20 rank structures from the CS after docking to TryR. Calculated Tanimoto similarity coefﬁcient with respect to quinacrine mustard
(in parenthesis).
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weighted to the standard error, and these values are given in
Table 1.
Gratifyingly some of the best hits by consensus scoring (1,
5, 6, 10) displayed good inhibitory activity against TryR from
both species of parasite, with IC50 values ranging between
21-56 µM. To shed some light about the probable binding
modes of these ligands, a computational model of the complex
between TryR and the 2-(3-(2-chloro-10H-phenothiazin-0-yl)-
3-oxopropyl) decahydropyrido[1,2-a]pyrazine-2,5-diium (1) and
1-(10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-ethylpiperazine-
1,4-diium (5) as well as the protein-ligand interactions involved
according to the Ligplot software are depicted in Figure 8. Of
particular importance for substrate speciﬁcity are ﬁve residues
in the disulﬁde substrate binding site that are not conserved when
comparing TryR and human GR: Glu19, Trp22, Ser110,
Met114, and Ala343. As shown in Figure 8, the low-energy
model for both ligands exhibited contacts with several of these
key residues in accordance with a pure competitive type of
inhibition.
Three possible binding modes were calculated for compound
1 at the active site, Figure 8a. Consensus scoring predicted a
very speciﬁc hydrogen bond interaction with the oxygen atom
of Glu19 side chain and placed the pyridopyrazine-2,5-diium
moiety near Trp22, Tyr111, and Leu18. This is the region in
TryR that also ﬁxes the spermidine moiety (Spd site) and is
thus responsible for the mutually exclusive substrate speciﬁcities
when comparing the parasite TryR and human GR.
13 In turn.
the phenothiazine ring exhibits hydrophobic interactions with
Ile339, Pro336. and Asn340. These residues form a pocket that
has been reported to accommodate the γGluI component of
T[S]2,
13 Figure 8b. In contrast to the binding mode predicted
Figure 7. Compounds selected from the database for TryR inhibition screening. Calculated Tanimoto similarity coefﬁcient with respect to quinacrine
mustard (in parenthesis).
Table 1. Inhibition of TryR by Selected Compounds Retrieved from the
Virtual Screening Cascade Protocol and their Rankings by Consensus
Scoring (CS), AutoDock (AD), and X-Score (XS)
compd CS AD XS
T. cruzi
TryR IC50 (µM)
T. brucei
TryR IC50 (µM)
1 1 4 15 35.4 ( 1.5 31.9 ( 1.4
2 22 7 2 >100 >100
3 32 6 9>100 >100
4 4 28 14 78.7 ( 8.2 >100
5 5 15 76 29.1 ( 1.1 36.0 ( 1.1
6 6 5 83 21.8 ( 1.2 54.3 ( 4.8
7 74 98 9 >100 >100
10 10 21 58 56.3 ( 6.9 46.9 ( 6.0
12 12 69 16 >100 >100
16 16 83 6 >100 >100
21 70 8 259 >100 >100
22 112 191 1 >100 >100
23 23 46 3 84.4 ( 4.4 >100
24 44 36 4 >100 >100
25 26 29 57 11.5 ( 0.4 14.6 ( 0.8
26 28 68 126 36.7 ( 2.2 37.3 ( 1.1
27 34 153 77 75.3 ( 3.2 58.7 ( 2.0
28 27 134 36 45.2 ( 2.8 >100
29 227 105 305 >100 >100
1676 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 6 Perez-Pineiro et al.by consensus scoring, the other two calculated conformations
positioned the phenothiazine ring near the Spd site and,
according to X-Score, the positively charged fragment is at
hydrogen bonding distance from Tyr111. On the other hand,
two very similar orientations were found for compound 5, Figure
8c. In both cases, the dithiepine ring is lodged near the Spd
site in close contact with residues Trp22, Met114, Leu18, and
Tyr11, meanwhile the heavily charged methylpiperazine-1,4-
diium moiety displays strong electrostatic interaction with
Glu19, Figure 8d.
A similar docking pattern was found for 3-((10H-phenothi-
azin-10-yl)methyl)-1-azoniabicyclo[2.2.2]octane (6), and N-meth-
yl-N-(2-oxo-2-(2-(phenylthio)phenylamino) ethyl)cyclohexan-
aminium (10). On the basis of these preliminary docking results,
we could assume that the presence of bulky quaternary amines
fragments in the analyzed molecules has an important role in
enhancing TryR binding afﬁnity. A possible explanation to this
fact could be the effective combination of strong electrostatic
and hydrophobic interactions between these positively charge
moieties and several key residues at the active site that are
intimately associated with substrate speciﬁcity.
Compounds 2 and 3, Table 1, showed poor correlation
between their theoretical binding afﬁnity and the experimental
inhibitory potency. A likely explanation for this fact could be
the lack of rigidity in the diphenylsulﬁde class and the
consequent difﬁculty to accurately predict the energy associated
with the ligand-receptor complex.
Compounds 12, 14, 16, and 20 are the only neutral molecules
among the 20 top ranked ligands. In contrast to positively
charged aromatic compounds, it has been found that neutral
species are less likely to induce host toxicity upon DNA binding
and they also possess a better availability to cross the blood-brain
barrier.
5 The latter property is particularly desirable in the
treatment of late-stage parasitic diseases when the parasite have
established themselves in the central nervous system.
5 According
to the results in Table 1, neither 12 nor 16 displayed signiﬁcant
inhibitory activity against TryR. In the same manner, some of
the best ranked ligands by AutoDock (21) and X-Score (22-
24) failed to show signiﬁcant inhibition at concentrations below
100 µM.
The low values of the Tanimoto similarity coefﬁcient, with
respect to the acridine quinacrine mustard, calculated for some
of the newly identiﬁed chemotypes depicted in Figure 6 and 7
(7, 0.21; 5, 0.18; 11, 0.23; 25, 0.19; 26, 0.15; 27, 0.21; 28, 0.18;
29, 0.26), also conﬁrm the good SHOP performance of the
implemented similarity strategy. In this context, the possibility
of identifying novel tricyclic-related inhibitors would be of great
value because most of the synthetic approaches in this area have
been focused toward the decoration of known templates rather
than the search for new tricyclic scaffolds.
15,18-20 Gratifyingly,
we found that molecules containing dibenzothiepine 5, diben-
zooxathiepine 25, and dibenzodithiepine 26 heterocycles as a
central core could be considered as suitable candidates to
increase the limited repertoire of existing tricyclic inhibitors.
Figure 8. View of possible binding modes of protonated compounds 1 (a) and 5 (c) in the active site of TryR predicted by consensus scoring
(pink), AutoDock (green), and X-Score (blue). Residues of the active site are shown in atomic colors. Predicted hydrophobic and electrostatic
interactions of compounds 1 (b) and 5 (d) at the active site according to Ligplot. Hydrogen bonds and length are represented by dotted lines.
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ranked molecules, and they have been used as inhibitors of
tumor necrosis factor-R,
49 DNA helicases,
50 as well as neuro-
tropic and psychotropic agents.
51
Moreover, these tricyclic derivatives displayed a good inhibi-
tory activity compound, 25 being the most potent among the
tested ligands with IC50 values of 11.5 and 14.6 µM for T. cruzi
and T. brucei TryR, respectively, Table 1. The preferred
conformation found for 3-((11H-dibenzo[b,e][1,4]oxathiepin-
11-yl)methyl)-1-methylpiperidinium (25) and 3-(11H-
dibenzo[b,e][1,4]dithiepin-11-yl)-N,N-dimethylpropan-1-amin-
ium (26) at the active cleft, and the ligand-protein interactions
involved are depicted in Figure 9. As expected, these compounds
display a binding pattern similar to that proposed for the tricyclic
inhibitors acridine and phenothiazine. Three modes of binding
were found for compound 25, Figure 9a. Even though all the
conformations anchored the tricyclic dibenzooxathiepine in the
proximity of the hydrophobic patch (Trp22, Met114, Tyr111,
Leu18), only AutoDock and consensus scoring positioned the
1-methylpiperidinium moiety at hydrogen bond distance from
Glu19, Figure 9b. A similar orientation was found for 26, Figure
9c. The bulky dibenzodithiepine moiety is anchored at the Spd
site (Trp22, Met114, Ser110), and the alkyl amino side chain
exhibits electrostatic interactions with Glu19 via hydrogen
bonding, Figure 9d.
The thia-3-azatetracyclo 27 and the 2,4,6-trioxohexahydro-
pyrimidine 28 also constitutes novel chemotypes found among
the top rank molecules. Compound 27 possesses moderate
inhibitory activity (58-75 µM), meanwhile 28 shows an
unexpected selectivity for inhibiting T. cruzi TryR (45 µM)
because little inhibition was detected under 100 µM for T. brucei
TryR.
Recently, the importance of terminally substituted guanidines
and biguanides for antitrypanosomal activity has been high-
lighted. The biguanide clorhexidine,
18 and several alkylpolyami-
noguanidines and alkylpolyaminobiguanides,
52 have shown
potent inhibitory activity against TyrR. Assuming that these
derivatives would produce an entropy penalty upon binding,
the employment of 4-oxo-1,4,5,5-tetrahydropyrimidin-2-yl-pip-
erazin-1-ium 29, as a conformationally constrained bioisosters
of guanidine, seems to be a viable alternative. Nevertheless,
this compound failed to show signiﬁcant inhibition at concentra-
tions below 100 µM.
Conclusions
The development of a novel virtual screening cascade protocol
to identify potential inhibitors of the parasitic enzyme trypan-
othione reductase has been described. On the basis of molecular
fragment proﬁles, a similarity search on the ZINC database was
performed by the “miscreen” program using known reversible
inhibitors of TryR as reference structures. After ADME/TOX
ﬁltering, the resulting enriched library was docked into the
binding site of TryR to provide a list of putative ligands ranked
according to consensus scoring. Clustering analysis and Tan-
Figure 9. View of possible binding modes of compounds 25 (a) and 26 (c) in the active site of TryR predicted by consensus scoring (pink),
AutoDock (green) and X-Score (blue). Residues of the active site are shown in atomic colors. Predicted hydrophobic and electrostatic interactions
of compounds 25 (b) and 26 (d) at the active site according to Ligplot. Hydrogen bonds and length are represented by dotted lines.
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provement of the molecular diversity of the enriched library
with respect to the initial training set. The study of electrostatic
and hydrophobic interactions of the best hits at the active cleft
highlighted the importance of conformationally constrained
quaternary amine moieties in enhancing TryR binding afﬁnity.
Enzymatic inhibition assays on T. cruzi and T. brucei TryR
conﬁrmed the inhibitory effect of some of the top ranked ligands.
In addition, the scaffold hopping (SHOP) process derived from
the developed computational approach allowed the identiﬁcation
of several chemotypes not previously tested as antiprotozoal
agents. To our knowledge, this is the ﬁrst report about the
inhibitory effect of molecules-containing dibenzothiepine, diben-
zooxathiepine, dibenzodithiepine, thiaazatetracyclo, and 2,4,6-
trioxohexahydro pyrimidine on trypanothione reductase. Further
rational optimization of these polycyclic ring systems and the
bioscreening of the rest of the structures contained in the
database are the theme of future research.
Experimental Section
Compounds used for inhibitory testing were supplied by different
commercial sources. Compounds 5 (salt, CH3SO3H), 24, 25 (salt,
HOOCCOOH), 26 (salt, HOOCCOOH), and 27 (salt, Cl- H2O)
were from SPECS (http:www.specs.net); 3, 4 (salt, HCl), and 22
were from Chembridge (http:www.chembridge.com); 6, 7 (salt,
Cl-), and 28 (salt, I) were from IBScreen (http:www.ibscreen.com);
2, 10, 12, 16, 23, and 29 were from Enamine (http:www.
enamine.net); 1 (salt 2 × HOOCCHCHCOOH) was from TimTec
(http:www.timtec.net), and 21 (salt CO3
2-) was from Bachem.
The purity of the tested compounds was determined by liquid
chromatography-MS (Phenomenex Gemini C18 column, 50 mm
× 3.0 mm, 5 µm particle size; mobile phase, water/acetonitrile
+0.1% HCOOH 80:20 to 5:95 over 3.5 min and then held for 1.5
min; ﬂow rate 0.5 mL/min). Samples were diluted with acetonitrile/
water (1:1) and analyzed using UV detection at 254 nm. According
to the analytical data the purity of the tested compounds is higher
than 95% except for compound 10 (43%).
Enzymatic assays. Inhibition of TryR was carried out in a
microplate format as described previously.
45 Assays were set up
in 96-well plates using a Biotek Precision 2000 automated liquid
handler and initiated using NADPH. The ﬁnal assay mixtures (0.18
mL) contained TR (20 mU/mL) in the presence of 40 mM Hepes
(pH 7.5), 1 mM EDTA, 0.15 mM NADPH, 50 µM 5,5′ -dithio-
bis(2-nitrobenzoic acid), 6 µM T[S]2, and inhibitor (100 µMt o1 0
nM in 3-fold serial dilutions). The linear rate of thionitrobenzoate
ion formation was monitored over 5 min in a Spectramax 340PC
plate reader (Molecular Devices) at 412 nm. Raw data was
processed using Microsoft Excel. Graﬁt 5.0 (Erithacus software)
was used to ﬁt the data to a three-parameter equation to determine
IC50 values. IC50 determinations were carried out in triplicate for
each compound and the mean weighted to standard error calculated.
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